Biophore receives sub-licence from MPP to manufacture and market Molnupiravir EP News Bureau Jan 21, 2022 The company has received DCGI regulatory license for the Indian market, applicable for both API as well as the finished product
Biophore applies for DCGI approval for emergency use of Aviptadil to treat COVID-19 EP News Bureau Jun 11, 2021 The company informed that it will be commencing commercial production immediately after the approval is received
Biophore ramps up Made-In-India Favipiravir production for Covid-19 EP News Bureau Jul 14, 2020 Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well
